Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcome and safety events: A meta-analysis of randomized controlled clinical trials

BACKGROUND: The clinical benefit of sodium-glucose cotransporter 2 (SGLT2) inhibitors for preventing and treating cardiovascular events remains controversial. We aimed to study the effect of SGLT2 inhibitors on cardiovascular outcomes and safety events, giving particular attention to the benefits in...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Chen, Shen, Shi-Chun, Zhang, Ke, Zhou, Lei, Shen, Jun-Jie, Zhao, Jia-Ying, Ding, Sheng-Gang, Ma, Li-kun, Gao, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9613919/
https://www.ncbi.nlm.nih.gov/pubmed/36312269
http://dx.doi.org/10.3389/fcvm.2022.926979

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9613919/
https://www.ncbi.nlm.nih.gov/pubmed/36312269
http://dx.doi.org/10.3389/fcvm.2022.926979

Ejemplares similares